Rivas Mauricio, Acevedo Francisco, Dominguez Francisco, Galindo Hector, Camus Mauricio, Oddo David, Villarroel Alejandra, Razmilic Dravna, Peña Jose, Munoz Medel Matias, Navarro Maria Elena, Perez-Sepulveda Alejandra, Medina Lidia, Merino Tomas, Briones Juan, Kalergis Alexis, Sanchez Cesar
Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile. Email:
Department of Oncological and Maxillofacial Surgery, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Asian Pac J Cancer Prev. 2019 Jul 1;20(7):2209-2212. doi: 10.31557/APJCP.2019.20.7.2209.
Objective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was to determine a relationship between the neutrophil to lymphocyte ratio (NLR) prior to NAC, BC subtypes and the probability of a pathologic complete response (pCR). Materials and Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data collected included peripheral blood cell counts, BC subtype at diagnosis and the pathology report of surgery after chemotherapy. Results: A total of 88 patients were analyzed. Approximately, a 25% had a pCR, and displayed a significant correlation between BC subtype and pCR (p= 0.0138 Chi2); this was more frequent in epidermal growth factor receptor type 2 (HER2) enriched subtype patients (54%). Luminal B BC patients with a pCR had significantly lower NLR levels (t test, p= 0.0181). Conclusions: HER2-enriched tumors had a higher probability of pCR. In Luminal B tumors, NLR had a statistically significant relationship with the probability of pCR. In this subtype, NLR could be a useful biomarker to predict tumor response to NAC. Further studies including other clinical parameters for systemic inflammation such as platelet counts, intratumoral NLR or body mass index could help identify patients that would get the most benefit from NAC.
乳腺癌（BC）患者对新辅助化疗（NAC）的肿瘤反应是总生存期的一个预测指标。我们研究的目的是确定NAC治疗前的中性粒细胞与淋巴细胞比值（NLR）、BC亚型与病理完全缓解（pCR）概率之间的关系。材料与方法：回顾性收集了来自UC-Christus健康网络癌症中心的病历。收集的临床数据包括外周血细胞计数、诊断时的BC亚型以及化疗后手术的病理报告。结果：共分析了88例患者。约25%的患者达到pCR，且BC亚型与pCR之间存在显著相关性（卡方检验，p = 0.0138）；这在富含表皮生长因子受体2（HER2）的亚型患者中更为常见（54%）。达到pCR的管腔B型BC患者的NLR水平显著较低（t检验，p = 0.0181）。结论：富含HER2的肿瘤pCR概率更高。在管腔B型肿瘤中，NLR与pCR概率存在统计学上的显著关系。在该亚型中，NLR可能是预测肿瘤对NAC反应的有用生物标志物。纳入其他全身炎症临床参数（如血小板计数、肿瘤内NLR或体重指数）的进一步研究可能有助于识别能从NAC中获益最大的患者。
